Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2003
09/18/2003US20030176461 Aminopiperidines
09/18/2003US20030176460 Piperidine compounds for use as ccr-3 inhibitors
09/18/2003US20030176457 Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
09/18/2003US20030176456 Administrering antagonist of alpha 1 containing GABAA receptors to produce an anti-anxiolytic effect for reducing anxiety in a patient
09/18/2003US20030176455 Inhibiting cell death following cellular regeneration in a mammal in need thereof, which comprises providing with an effective amount of a rapamycin
09/18/2003US20030176453 Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use therefor
09/18/2003US20030176452 Oral absorption
09/18/2003US20030176451 Reacting a heterocyclic-methanesulfonyl substituted-quinazolineamine compound with amine compound
09/18/2003US20030176450 Pyrazolopyrimidines
09/18/2003US20030176449 For therapy and prophylaxis of adverse conditions of the central nervous system, including anxiety, convulsions and cognitive disorders
09/18/2003US20030176448 Mitochondria protecting agents for treating mitochondria associated diseases
09/18/2003US20030176447 For therapy of cardiovascular diseases such as atrial and ventricular arrhythmias, intermittent claudication, Prinzmetal's (variant) angina, stable and unstable angina, exercise induced angina, congestive heart disease
09/18/2003US20030176446 2,2-disubstituted 1,3-dioxolanes as antitussive agents
09/18/2003US20030176445 Substituted 1,4-dihydropyridine compounds as bradykinin antagonists
09/18/2003US20030176444 For therapy of inflammation
09/18/2003US20030176443 Pyridylpyrimidine derivatives as effective compounds against prion diseases
09/18/2003US20030176442 Administering cGMP PDE5 inhibitor for therapy of diabetic ulcers
09/18/2003US20030176441 Inhibitsthe binding of eotaxin to the CCR-3 receptor and thereby provide a means of combating eosinophil induced diseases, such as asthma
09/18/2003US20030176439 For therapy and prophylaxis of thromboembolic diseases and restenoses; reversible inhibitors of the blood clotting enzyme factor VIIa
09/18/2003US20030176438 Useful as adjuvants to chemotherapy or radiation therapy in the treatment of cancer; as inhibitors of checkpoint kinase Cds1 (in man also known as Chk2)
09/18/2003US20030176437 Anti-inflammatory and protein kinase inhibitor compositions and related methods for downregulation of detrimental cellular responses and inhibition of cell death
09/18/2003US20030176436 For therapy and prophylaxis of bacterial infections, or their use as antiseptics, sterilizants, or disinfectants
09/18/2003US20030176435 Binding to the NMDA receptor glycine site have utility for the amelioration of pain and particularly for amelioration of neuropathic pain
09/18/2003US20030176434 Compounds and methods for promoting smoking cessation
09/18/2003US20030176433 For therapy and prophylaxis of hepatitis C virus (HCV) infection
09/18/2003US20030176432 Cyclic and heterocyclic N-substituted alpha-iminohydroxamic and -carboxylic acids
09/18/2003US20030176431 Compounds, compositions and methods for preventing and treating pestivirus infection and associated diseases
09/18/2003US20030176430 For therapy and prophylaxis of Tachykinin-mediated diseases
09/18/2003US20030176429 2-thio-4h-3,1-benzoxazin-4-one derivatives for use as enzyme inhibitors
09/18/2003US20030176426 Administering imidazolium salt of dicyclohexyl compound for therapy
09/18/2003US20030176425 Novel 1,2,4-thiadiazole derivatives as melanocortin receptor modulators
09/18/2003US20030176424 Delivering to the axon a therapeutically effective amount of a specific inhibitor of protein kinase C, whereby regenerative growth of the axon is promoted; detecting a resultant promotion of the regenerative growth of the axon
09/18/2003US20030176423 Delivering to the axon a therapeutically effective amount of a specific inhibitor of protein kinase C, whereby regenerative growth of the axon is promoted; and detecting a resultant promotion of the regenerative growth of the axon
09/18/2003US20030176422 Pyridoarylphenyl oxazolidinone antibacterials, and related compositions and methods
09/18/2003US20030176421 Administering therapeutically effective amount of an inhibitor of phosphodiesterase-4 (PDE4), including isozyme subtypes thereof for therapy and prophylaxis of stasis in all or any part or parts of the stomach of a patient
09/18/2003US20030176420 Treatment of T-helper cell type 2-mediated immune diseases by retinoid antagonists
09/18/2003US20030176419 As inhibitors of the retinoic acid-metabolism, as drugs
09/18/2003US20030176418 For therapy of Alzheimer's disease, Parkinson's disease, schizophrenia, Huntington's chorea, Friederich's ataxia, Gilles de la Tourette's Syndrome, Down Syndrome, Pick disease, dementia, clinical depression, age- related cognitive decline
09/18/2003US20030176417 Reversing advanced glycosylation cross-links using heterocyclic-substituted thiazolium compounds
09/18/2003US20030176416 For therapy of disease, disorder or condition is responsive to modulation of cholinergic receptors and/or monoamine receptors
09/18/2003US20030176415 1,2,3,4-tetrahydroisoquinoline derivatives
09/18/2003US20030176413 Polycyclic guanine derivative phosphodiesterase V inhibitors
09/18/2003US20030176412 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists
09/18/2003US20030176411 Photodynamic therapy for pre-melanomas
09/18/2003US20030176410 Platinum (II) antitumor compounds
09/18/2003US20030176409 Administering a low dose of estrogen to mammal
09/18/2003US20030176408 For topical application, penetration
09/18/2003US20030176407 Carbonate and carbamate modified forms of glucocorticoids
09/18/2003US20030176406 Polycaprolactone-b-poly (ethylene oxide) copolymer non-cross-linked micelles as a delivery vehicle for steroid
09/18/2003US20030176405 8 Beta-hydrocarbyl-substituted estratrienes for use as selective estrogens
09/18/2003US20030176404 Progestogen-anti-progestogen regimens
09/18/2003US20030176403 Combination chemotherapy
09/18/2003US20030176402 Nematicidal compositions and methods
09/18/2003US20030176401 Sodium salt of an azo derivative of 5-aminosalicylic acid
09/18/2003US20030176400 For therapy of allergic diseases such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma, food allergy, etc., systemic mastocytosis
09/18/2003US20030176399 Pharmaceutical formulations comprising indolinone derivatives
09/18/2003US20030176398 Prodrugs of GABA analogs, compositions and uses thereof
09/18/2003US20030176397 Unique compositions of zwitterionic phospholipids and bisphosphonates and use of the compositions as bisphosphate delivery systems with reduced GI toxicity
09/18/2003US20030176394 Using an alginate having a molecular weight of more than 30, 000 and leas than 380,000 in the manufacture of pharmaceutical formulation for the inhibition of the proteolytic activity of pepsin and/or gastric juice in a mammal
09/18/2003US20030176393 Product of heat treatment of uronic acid, food, drink or drug including the product
09/18/2003US20030176392 Administering 5-substituted uracil-nucleosides or its pharmaceutically acceptable salt or prodrug for therapy of infected with Epstein-Barr virus or Kaposi's sarcoma-associated herpes ("KHSV")
09/18/2003US20030176391 Oral fludara of high-purity formulation with quick release of active ingredient
09/18/2003US20030176390 Methods of treating insulin resistance syndrome and diabetes
09/18/2003US20030176389 Administering to a subject suffering from gastrointestinal inflammation a formulation comprising an immunomodulatory nucleic acid to the subject, the immunomodulatory nucleic acid comprising the sequence 5'-CpG-3'
09/18/2003US20030176388 Fatty acid synthase mRNA binding protein
09/18/2003US20030176383 Antisense modulation of p38 mitogen activated protein kinase expression
09/18/2003US20030176381 Hyaluronic acid in the treatment of cancer
09/18/2003US20030176379 Useful in the administration of a drug, therapy
09/18/2003US20030176374 Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
09/18/2003US20030176373 Agents that modulate DNA-PK activity and methods of use thereof
09/18/2003US20030176372 Anti-virus agent
09/18/2003US20030176370 Anti-viral pyrimidine nucleoside analogues
09/18/2003US20030176369 Stabilized azithromycin compositions
09/18/2003US20030176368 For therapy of cancer
09/18/2003US20030176367 Use of sublethal concentrations of anti-invasin compounds to therapeutically or prophylactically treat fungal infections
09/18/2003US20030176366 Topical application of ascorbic acid compounds for augmenting the synthesis of epidermal ceramides
09/18/2003US20030176365 To improve cerebral function
09/18/2003US20030176364 Antimicrobial therapeutic compositions and methods of use
09/18/2003US20030176363 For therapy of T lymphocyte mediated inflammatory diseases in animals and man
09/18/2003US20030176362 For therapy of epilepsy
09/18/2003US20030176361 Having cytoprotective activity and protective activity for neuroinflammation, and neurodegenerative disorders; for use in therapy of stroke, cerebral ischemia, myocardial infarction, myocardial ischemia, chronic heart failure, inflammation
09/18/2003US20030176359 Administration of a thiol-based chemoprotectant compound
09/18/2003US20030176357 Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels
09/18/2003US20030176356 Endothelin antagonists and endothelin-converting enzyme inhibitors for the treatment of glaucoma
09/18/2003US20030176341 For use as an anti-viral, anti-tumour or immunomodulatory agent
09/18/2003US20030176336 Novel human ulip/crmp protein and use thereof in diagnosis and treatment of cancers and paraneoplastic neurological syndromes
09/18/2003US20030176332 Novel use of cytokine inhibitors
09/18/2003US20030176324 Derivatives of water insoluble drugs which exhibit good activity and water solubility
09/18/2003US20030176320 For therapy of cancer, autoimmune diseases and restenosis; efficiency
09/18/2003US20030176319 N4-acylcytosine-1,3- dioxolane nucleosides for treatment of viral infections
09/18/2003US20030176318 Administering a therapeutically effective amount of a temporary p53 inhibitor to an individual suffering from the disease or condition
09/18/2003US20030176317 Stabilization of hypoxia inducible factor (HIF) alpha
09/18/2003US20030176316 Methods for treatment of rheumatoid arthritis
09/18/2003US20030176314 Administering to the subject an amount of a compound effective to treat pain in the subject, wherein the compound binds to a Neuropeptide FF (NPFF) receptor
09/18/2003US20030175950 RNA interference mediated inhibition of HIV gene expression using short interfering RNA
09/18/2003US20030175934 Controlling cell differentiation, cell proliferation; anticancer agents
09/18/2003US20030175901 Genetic engineering; polyketides
09/18/2003US20030175898 Isolated nucleic acids; immune response disease
09/18/2003US20030175881 Nucleic acids encoding (poly) peptides having chips activity
09/18/2003US20030175876 a neurotrophin with biological activity on the central/peripheral nervous system cells; used for treating GDNF-responsive conditions such as alzhiemer's, parkinsons; device for nerve damage treatment
1 ... 5338 5339 5340 5341 5342 5343 5344 5345 5346 5347 5348 5349 5350 5351 5352 5353 5354 5355 5356 5357 5358 ... 7860